CA125 effects on humoral immunosuppression

Kline, J. Bradford; Nicolaides, Nicholas C.

doi:10.18632/aging.101301

Cited by 1 publication

(1 citation statement)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MUC1 undergoes various glyco-modifications during ovarian cancer progression [ 191 ], and is also overexpressed in other adenocarcinomas and haematological malignancies [ 86 ]. MUC16 is overexpressed primarily in ovarian cancer [ 86 ] with soluble, tumour-shed antigens or membrane bound forms able to suppress humoral-based immunity, particularly antibody-dependent cell-mediated cytotoxicity (ADCC) [ 192 , 193 ]. These mucins are ligands for Siglecs, inhibitory receptors on innate and adaptive immune cells that may contribute to dampening of the immune response against tumours.…”

Section: Cancer and Immune System Interactionsmentioning

confidence: 99%

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

Macpherson

Barry

Ricciardelli

et al. 2020

JCM

View full text Add to dashboard Buy / Rent full text

Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still under development and being tested in numerous clinical trials. A detailed understanding of the interactions between cancer and the immune system is vital for optimisation of immunotherapies either alone or when combined with chemotherapy and other therapies. This article, in two main parts, provides an overview of: (1) components of the normal immune system and current knowledge regarding tumour immunology, biology and their interactions; (2) strategies, and targets, together with challenges and potential innovative approaches for cancer immunotherapy, with attention given to epithelial ovarian cancer.

show abstract